论文部分内容阅读
2015年5月1日,中国科学院上海生命科学研究院生物化学与细胞生物学研究所季红斌研究员带领的研究团队联合复旦大学附属肿瘤医院陈海泉教授团队的最新研究成果,首次揭示了LKB1缺失引起的氧化还原态失衡可调控非小细胞肺癌的可塑性及药物响应,并以“LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-Small Cell Lung Cancer Plasticity and Therapeutic Response”为题,在线发表于Cancer Cell杂志.肺癌是当今全球范围内危害性最大的疾病之一,具有高发病率和高致死率,且五年存活率仅为15%.在我国,
On May 1, 2015, the research team led by Ji Hongbin, a researcher at the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and the latest research results from the team of Professor Chen Haiquan, affiliated to Oncology Hospital of Fudan University, revealed for the first time the oxidation induced by LKB1 deletion Reduced state imbalances regulate plasticity and drug response in non-small cell lung cancer and are published online in Cancer Cell magazine entitled “LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-Small Cell Lung Cancer Plasticity and Therapeutic Response”. Is one of the most dangerous diseases in the world today, with high morbidity and high lethality, and the five-year survival rate is only 15% .In our country,